Skip to main content
Top
Published in: Infectious Agents and Cancer 1/2014

Open Access 01-12-2014 | Short report

Co-infection with HPV types from the same species provides natural cross-protection from progression to cervical cancer

Authors: Rafal S Sobota, Doreen Ramogola-Masire, Scott M Williams, Nicola M Zetola

Published in: Infectious Agents and Cancer | Issue 1/2014

Login to get access

Abstract

Background

The worldwide administration of bivalent and quadrivalent HPV vaccines has resulted in cross-protection against non-vaccine HPV types. Infection with multiple HPV types may offer similar cross-protection in the natural setting. We hypothesized that infections with two or more HPV types from the same species, and independently, infections with two or more HPV types from different species, associate with protection from high-grade lesions.

Findings

We recruited a cohort of 94 HIV, HPV-positive women from Botswana, with Grade 2 or higher cervical intraepithelial neoplasia. Infections with 2 or more HPV types from a single species associated with reduced lesion severity in univariate analysis (OR = 0.41, 95% CI 0.18-0.97, p = 0.042), when adjusted for the presence of HPV 16 or 18 types (OR = 0.41, 95% CI 0.17-1.00, p = 0.049), or all high-risk HPV type infections (OR = 0.38, 95% CI 0.16-0.90, p = 0.028). Infections with 2 or more HPV types from different species did not associate (OR = 0.68, 95% CI 0.25-1.81, p = 0.435).

Conclusions

Our findings show that co-infections with genetically similar HPV types reduce the likelihood of progression to high-grade lesions in HIV positive women, an effect not observed in co-infections with taxonomically different HPV types. This observation is possibly caused by an immune cross-protection through a similar mechanism to that observed after HPV vaccination.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Canc J Int Canc. 2010, 127 (12): 2893-2917.CrossRef Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Canc J Int Canc. 2010, 127 (12): 2893-2917.CrossRef
2.
go back to reference Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999, 189 (1): 12-19.PubMedCrossRef Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999, 189 (1): 12-19.PubMedCrossRef
3.
go back to reference Schiffman M, Rodriguez AC, Chen Z, Wacholder S, Herrero R, Hildesheim A, Desalle R, Befano B, Yu K, Safaeian M: A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia. Cancer Res. 2010, 70 (8): 3159-3169.PubMedPubMedCentralCrossRef Schiffman M, Rodriguez AC, Chen Z, Wacholder S, Herrero R, Hildesheim A, Desalle R, Befano B, Yu K, Safaeian M: A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia. Cancer Res. 2010, 70 (8): 3159-3169.PubMedPubMedCentralCrossRef
4.
go back to reference Burk RD, Chen Z, Van Doorslaer K: Human papillomaviruses: genetic basis of carcinogenicity. Publ Health Genomics. 2009, 12 (5–6): 281-290.CrossRef Burk RD, Chen Z, Van Doorslaer K: Human papillomaviruses: genetic basis of carcinogenicity. Publ Health Genomics. 2009, 12 (5–6): 281-290.CrossRef
5.
go back to reference de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H: Classification of papillomaviruses. Virology. 2004, 324 (1): 17-27.PubMedCrossRef de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H: Classification of papillomaviruses. Virology. 2004, 324 (1): 17-27.PubMedCrossRef
6.
go back to reference Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers EM: Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology. 2010, 401 (1): 70-79.PubMedPubMedCentralCrossRef Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers EM: Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology. 2010, 401 (1): 70-79.PubMedPubMedCentralCrossRef
7.
go back to reference Guindon S, Gascuel O: A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst Biol. 2003, 52: 696-704.PubMedCrossRef Guindon S, Gascuel O: A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst Biol. 2003, 52: 696-704.PubMedCrossRef
9.
go back to reference Schiffman M, Clifford G, Buonaguro FM: Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agents Canc. 2009, 4: 8-CrossRef Schiffman M, Clifford G, Buonaguro FM: Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agents Canc. 2009, 4: 8-CrossRef
10.
go back to reference Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL: Chapter 3: HPV type distribution in women with and without cervical neoplastic diseases. Vaccine. 2006, 24 (Suppl 3): 26-34.CrossRef Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL: Chapter 3: HPV type distribution in women with and without cervical neoplastic diseases. Vaccine. 2006, 24 (Suppl 3): 26-34.CrossRef
11.
go back to reference Barr E, Tamms G: Quadrivalent human papillomavirus vaccine. Clin Infect Dis: Offic Publ Infect Dis Soc Am. 2007, 45 (5): 607-609. Barr E, Tamms G: Quadrivalent human papillomavirus vaccine. Clin Infect Dis: Offic Publ Infect Dis Soc Am. 2007, 45 (5): 607-609.
12.
go back to reference Jaquet A, Horo A, Ekouevi DK, Toure B, Coffie PA, Effi B, Lenaud S, Messou E, Minga A, Sasco AJ: Risk factors for cervical intraepithelial neoplasia in HIV-infected women on antiretroviral treatment in Côte d'Ivoire. West Africa PLoS One. 2014, 9 (3): e90625-PubMedCrossRef Jaquet A, Horo A, Ekouevi DK, Toure B, Coffie PA, Effi B, Lenaud S, Messou E, Minga A, Sasco AJ: Risk factors for cervical intraepithelial neoplasia in HIV-infected women on antiretroviral treatment in Côte d'Ivoire. West Africa PLoS One. 2014, 9 (3): e90625-PubMedCrossRef
13.
go back to reference Keam SJ, Harper DM: Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix]. Drugs. 2008, 68 (3): 359-372.PubMedCrossRef Keam SJ, Harper DM: Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix]. Drugs. 2008, 68 (3): 359-372.PubMedCrossRef
14.
15.
go back to reference Malagon T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, Brisson M: Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012, 12 (10): 781-789.PubMedCrossRef Malagon T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, Brisson M: Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012, 12 (10): 781-789.PubMedCrossRef
16.
go back to reference Siddiqui MA, Perry CM: Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil). Drugs. 2006, 66 (9): 1263-1271. discussion 1272-1263PubMedCrossRef Siddiqui MA, Perry CM: Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil). Drugs. 2006, 66 (9): 1263-1271. discussion 1272-1263PubMedCrossRef
17.
go back to reference Camargo M, Soto-De Leon SC, Munoz M, Sanchez R, Peňa-Herrera D, Pineda-Peňa AC, Sussmann O, Paez C, Perez-Prados A, Patarroyo ME: Human papillomavirus detection in women with and without human immunodeficiency virus infection in Colombia. BMC Cancer. 2014, 14 (1): 451-PubMedPubMedCentralCrossRef Camargo M, Soto-De Leon SC, Munoz M, Sanchez R, Peňa-Herrera D, Pineda-Peňa AC, Sussmann O, Paez C, Perez-Prados A, Patarroyo ME: Human papillomavirus detection in women with and without human immunodeficiency virus infection in Colombia. BMC Cancer. 2014, 14 (1): 451-PubMedPubMedCentralCrossRef
Metadata
Title
Co-infection with HPV types from the same species provides natural cross-protection from progression to cervical cancer
Authors
Rafal S Sobota
Doreen Ramogola-Masire
Scott M Williams
Nicola M Zetola
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Infectious Agents and Cancer / Issue 1/2014
Electronic ISSN: 1750-9378
DOI
https://doi.org/10.1186/1750-9378-9-26

Other articles of this Issue 1/2014

Infectious Agents and Cancer 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine